

Date: 11 March 2022

**Re: Freedom of Information Request**  
**Ref: 47-2022**

Thank you for your email dated the 17/2/2022, requesting information in relation to non-small cell lung cancer.

The information that you require is as follows:

**Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:**

- Afatinib 19
- Alectinib 10
- Atezolizumab monotherapy 26
- Atezolizumab with chemotherapy 6
- Bevacizumab 0
- Brigatinib 6
- Ceritinib 1
- Crizotinib 3
- Dacomitinib 2
- Dabrafenib with Trametinib 0
- Docetaxel monotherapy or combination with Carboplatin/Cisplatin 5
- Durvalumab 11
- Erlotinib 12
- Gefitinib 1
- Gemcitabine 0
- Lorlatinib 6
- Nintedanib with Docetaxel 6
- Nivolumab 3
- Osimertinib 43
- Paclitaxel 0
- Pembrolizumab monotherapy 127

- Pembrolizumab with chemotherapy **10**
- Pemetrexed with Carboplatin/Cisplatin **61**
- Tepotinib **0**
- Vinorelbine with Carboplatin/Cisplatin **46**
- Any other active systemic anti-cancer therapy (SACT) **101**
- Palliative care only **Information not held**

**Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:**

- Atezolizumab monotherapy **7**
- Atezolizumab with chemotherapy **0**
- Durvalumab **5**
- Gemcitabine **0**
- Nivolumab **3**
- Osimertinib **0**
- Paclitaxel **0**
- Pembrolizumab (Keytruda) Mono **35**
- Pembrolizumab (Keytruda) with Chemotherapy **8**
- Other active systemic anti-cancer therapy (SACT) **2 patients – Docetaxel, 1 patient - Lorlatinib, 13 patients – Vinorelbine with Carboplatin/Cisplatin, 20 patients – other**
- Palliative care only **Information not held**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**

Kind Regards,

Margaret Moore  
Information Governance Administrator  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)